Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Brainsway Ltd BRSYF


Primary Symbol: BWAY

Healthcare Medical Devices
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BWAY)

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS(TM) Treatment December 1, 2025

GlobeNewswire 10 days ago

BrainsWay Launches First Clinical Trial of Deep TMS 360(TM) System for Alcohol Use Disorder

GlobeNewswire November 17, 2025

BrainsWay Receives FDA Clearance of Deep TMS(TM) as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

GlobeNewswire November 13, 2025

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

GlobeNewswire November 11, 2025

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

GlobeNewswire November 4, 2025

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

GlobeNewswire October 28, 2025

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

GlobeNewswire October 27, 2025

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

GlobeNewswire September 16, 2025

Neurolief Prepares for Launch of its Proliv(TM)Rx System for Major Depressive Disorder with Strategic Investment from BrainsWay

PR Newswire August 21, 2025
View More News ››

Opinion & Analysis (NDAQ:BWAY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BWAY)

Be the first to post on this bullboard.

Geodrill Limited

Geodrill Limited

Geodrill Limited, together with its subsidiaries, provides mineral exploration drilling services to the mining companies in ...
View More »